Related references
Note: Only part of the references are listed.High-sensitivity flow cytometric assays: Considerations for design control and analytical validation for identification of Rare events
Ulrike Sommer et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2021)
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser et al.
BLOOD (2021)
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia
Sanam Loghavi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback (Part 2A-Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation Part 2B-Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine)
Susan Spitz et al.
BIOANALYSIS (2021)
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia
Abhishek Maiti et al.
BLOOD ADVANCES (2021)
Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation
Piyanuch Kongtim et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML
Harald Herrmann et al.
BLOOD ADVANCES (2020)
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML
Nicholas J. Short et al.
BLOOD ADVANCES (2020)
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation
Samer A. Srour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia
Lauren VeltriVeltri et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3-Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)
Steven Piccoli et al.
BIOANALYSIS (2019)
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Sanjay S. Patel et al.
BLOOD ADVANCES (2019)
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse
P. Boddu et al.
LEUKEMIA (2018)
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia
Mithun Vinod Shah et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Universal monitoring of minimal residual disease in acute myeloid leukemia
Elaine Coustan-Smith et al.
JCI INSIGHT (2018)
Evaluating measurable residual disease in acute myeloid leukemia
Farhad Ravandi et al.
BLOOD ADVANCES (2018)
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia
Farhad Ravandi et al.
CANCER (2017)
How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
Jie Xu et al.
CLINICS IN LABORATORY MEDICINE (2017)
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia
Juan Ouyang et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2016)
The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia
Juan Ouyang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Sue Richards et al.
GENETICS IN MEDICINE (2015)
Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future
J. M. Jaso et al.
BONE MARROW TRANSPLANTATION (2014)
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
Hong-Hu Zhu et al.
BLOOD (2013)
Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS - Part V - Assay Performance Criteria
Brent Wood et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)
Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia:: A multicenter study of 51 patients
F Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
